# HiFiBiO

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/hifibio

- Industry: Biotechnology
- Headquarters: Cambridge, US
- Website: www.hifibio.com
- Total disclosed funding: $180M
- Latest round: Series D (Jun 14, 2021)
- Investors on record: 17

## About

Founded in 2013 and based in Cambridge, US, HiFiBiO Inc. is an emerging clinical stage multinational company that engages the use of human immune system to treat cancer and autoimmune disease.

The company's main business include development of immunomodulatory antibody products and single cell scientific research. It uses immunosuppressive cell types, suppression and stimulation pathways, and multi-effect immunomodulators to change the immune balance of cancer and autoimmune diseases. In addition, the company conducts single-cell research through solutions such as immune cell analysis, functional screening, and sequence-based deep phenotypic characterization, and applies droplet based microfluidic technology in conjunction with other single-cell approaches to drug discovery and drug development. 

The company will advance two lead antibody oncology assets into Phase I clinical trials – HFB200301, a novel anti-TNFR2 antibody and HFB301001, a differentiated second generation anti-OX-40 antibody.

## Funding rounds

- Series D, Jun 14, 2021, $75M — Hong Shan, IDG Capital, Legend Star, Mirae Asset Venture Investment, Maison Capital, B Capital, Sherpa Healthcare Partners, Hengxu Capital, Trinity Innovation Fund, HKSTP Ventures, Grand Mount Capital
- Series C, Aug 28, 2019, $67M — Hong Shan, IDG Capital, Kite Pharma, Inc., Legend Star, LYFE Capital, Virtus Inspire Ventures, Delian Capital
- Series B, May 16, 2018, $38M — Hong Shan, LYFE Capital, Virtus Inspire Ventures, Proxima Ventures, Nest.Bio Ventures
- Series A, Sep 1, 2016 — Nest.Bio Ventures

## Investors

- Nest.Bio Ventures (https://capitalatlas.ai/funds/nest-bio-ventures) — Series A, Series B
- Hong Shan — Series B, Series C, Series D
- LYFE Capital — Series B, Series C
- Virtus Inspire Ventures (https://capitalatlas.ai/funds/virtus-inspire-ventures) — Series B, Series C
- Proxima Ventures (https://capitalatlas.ai/funds/proxima-ventures) — Series B
- IDG Capital (https://capitalatlas.ai/funds/idg-capital) — Series C, Series D
- Kite Pharma, Inc. — Series C
- Legend Star (https://capitalatlas.ai/funds/legend-star) — Series C, Series D
- Delian Capital (https://capitalatlas.ai/funds/delian-capital) — Series C
- Mirae Asset Venture Investment (https://capitalatlas.ai/funds/mirae-asset-venture-investment) — Series D
- Maison Capital (https://capitalatlas.ai/funds/maison-capital) — Series D
- B Capital (https://capitalatlas.ai/funds/b-capital) — Series D
- Sherpa Healthcare Partners (https://capitalatlas.ai/funds/sherpa-healthcare-partners) — Series D
- Hengxu Capital (https://capitalatlas.ai/funds/hengxu-capital) — Series D
- Trinity Innovation Fund (https://capitalatlas.ai/funds/trinity-innovation-fund) — Series D
- HKSTP Ventures (https://capitalatlas.ai/funds/hkstp-ventures) — Series D
- Grand Mount Capital (https://capitalatlas.ai/funds/grand-mount-capital) — Series D